These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31195391)

  • 1. Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer.
    Izawa N; Sunakawa Y; Doi A; Arai H; Horie Y; Hirakawa M; Mizukami T; Ogura T; Tsuda T; Nakajima TE
    Oncology; 2019; 97(2):94-101. PubMed ID: 31195391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
    BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
    Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
    Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
    Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
    BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer.
    Natsume M; Shimura T; Iwasaki H; Okuda Y; Kitagawa M; Okamoto Y; Hayashi K; Kataoka H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1037-1046. PubMed ID: 30899983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
    Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
    Matsumoto H; Kawazoe A; Shimada K; Fukuoka S; Kuboki Y; Bando H; Kojima T; Ohtsu A; Yoshino T; Doi T; Shitara K
    BMC Cancer; 2018 Jan; 18(1):120. PubMed ID: 29385993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
    Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
    Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
    Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
    Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
    Parisi A; Cortellini A; Roberto M; Venditti O; Santini D; Dell'Aquila E; Stellato M; Marchetti P; Occhipinti MA; Zoratto F; Mazzuca F; Tinari N; De Tursi M; Iezzi L; Natoli C; Ratti M; Pizzo C; Ghidini M; Porzio G; Ficorella C; Cannita K
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2365-2373. PubMed ID: 31280347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical Experience of Ramucirumab for Treating Advanced Gastric Cancer].
    Kimura Y; Makari Y; Mikami J; Kamigaki S; Ikejima A; Fujii C; Sawada G; Nakahira S; Yamamura J; Nakata K; Yamamoto T; Ikeda N; Tsujie M; Fujita J; Ohzato H
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1193-1196. PubMed ID: 27760936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
    Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
    Mizukami T; Miyaji T; Narita Y; Matsushima T; Ogura T; Miyagaki H; Kawabata R; Horie Y; Kawaguchi T; Muro K; Hara H; Yamaguchi T; E Nakajima T
    Future Oncol; 2021 Jul; 17(19):2431-2438. PubMed ID: 33764163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].
    Chen LF; Fu GZ; Huang DP; Man Y; Jin Y; Dong QT; Huang YB; Chen YC; Wang HQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):977-983. PubMed ID: 31630497
    [No Abstract]   [Full Text] [Related]  

  • 17. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
    Cotes Sanchís A; Gallego J; Hernandez R; Arrazubi V; Custodio A; Cano JM; Aguado G; Macias I; Lopez C; López F; Visa L; Garrido M; Martínez Lago N; Fernández Montes A; Limón ML; Azkárate A; Pimentel P; Reguera P; Ramchandani A; Cacho JD; Martín Carnicero A; Granja M; Martín Richard M; Hernández Pérez C; Hurtado A; Serra O; Buxo E; Vidal Tocino R; Jimenez-Fonseca P; Carmona-Bayonas A
    PLoS One; 2020; 15(7):e0235848. PubMed ID: 32735623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.
    Paulson AS; Hess LM; Liepa AM; Cui ZL; Aguilar KM; Clark J; Schelman W
    Gastric Cancer; 2018 Sep; 21(5):831-844. PubMed ID: 29397460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan.
    Saito S; Muneoka Y; Ishikawa T; Akazawa K
    Clin Ther; 2017 Dec; 39(12):2380-2388. PubMed ID: 29175097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.